I disagree. I think there is a near 100% certainty that FY2009 will be cash flow positive, without factoring in the minimal BARDA revenues. BARDA is very important to the company, but not for the minimal revenues it generates. It is important for the huge costs it covers, and for the scientific data it generates.
Polynovo’s Novosorb is a med-tech Swiss Army Knife, page-18
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.02 |
Change
-0.045(2.18%) |
Mkt cap ! $1.395B | |||
| Open | High | Low | Value | Volume |
| $2.01 | $2.04 | $2.00 | $436.9K | 216.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 19693 | $2.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 16947 | 14 |
View Market Depth
| Last trade - 12.23pm 01/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |